Self Study Module 1 - Frontline Therapy for Patients With AML Without Targetable Mutations
Launch Date:
April 14, 2022
April 14, 2022
In this interactive video presentation, Dr. Eunice Wang presents optimal management strategies for patients who present with treatment-naive AML.
Eunice S. Wang, MD
Professor, Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Dr. Eunice Wang is the Chief of the Leukemia Service and Professor of Oncology at Roswell Park Comprehensive Cancer Center in Buffalo, New York, and is an Associate Professor, Department of Medicine, at the Jacobs School of Medicine & Biomedical Sciences, University of Buffalo. She earned her medical degree from the University of Southern California Keck School of Medicine and completed residency training in internal medicine at Yale-New Haven Hospital, New Haven, Connecticut, followed by a clinical hematology/oncology and research fellowship at Memorial Sloan Kettering Cancer Center in New York, New York.
Dr. Wang’s clinical research focuses on the development of early stage clinical trials for acute leukemias (AML, ALL) and myeloproliferative disorders. Her translational research interests involve the development of novel biological therapies targeting the bone marrow microenvironment for myeloid malignancies. Dr. Wang has authored/co-authored over 90 peer-reviewed articles, multiple book chapters, and editorials. She is a prior recipient of a NIH Cancer Clinical Investigator Team Leadership Award and a Mentored Research Scholar award from the American Cancer Society. Dr. Wang is certified by the American Board of Internal Medicine for internal medicine, medical oncology, and medical hematology. She is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and American Society of Hematology.
Dr. Wang’s clinical research focuses on the development of early stage clinical trials for acute leukemias (AML, ALL) and myeloproliferative disorders. Her translational research interests involve the development of novel biological therapies targeting the bone marrow microenvironment for myeloid malignancies. Dr. Wang has authored/co-authored over 90 peer-reviewed articles, multiple book chapters, and editorials. She is a prior recipient of a NIH Cancer Clinical Investigator Team Leadership Award and a Mentored Research Scholar award from the American Cancer Society. Dr. Wang is certified by the American Board of Internal Medicine for internal medicine, medical oncology, and medical hematology. She is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and American Society of Hematology.
Naval G. Daver, M.D.
Naval G. Daver, M.D.
Associate Professor, Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, TX
Dr. Naval Daver is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. He completed his medical school from Grant Medical College and Sir J group of Hospitals Mumbai, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine. He is a clinical investigator with a focus on molecular and immune therapies in AML and Myelofibrosis and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint and vaccine based approaches in AML, MDS, and myelofibrosis and is leading a number of these trials at MDACC. Dr. Daver has published >150 peer-reviewed manuscripts and is on the editorial board of numerous hematology specific journals. He has also authored numerous abstracts at national and international conferences.1.
Plan evidence-based therapeutic strategies for older unfit patients, those with preexisting comorbidities, and/or those with secondary AML using novel targeted agents or formulations and refinements of conventional chemotherapy
